Asclepii is creating the next generation of regenerative therapies through Artemis™, a revolutionary therapeutic platform that turns a US$30.000 autologous cell therapy into US$300.
Asclepii is creating the next generation of regenerative therapies through Artemis™, a revolutionary therapeutic platform that turns a US$30.000 autologous cell therapy into US$300.
Cell therapy is the future of human health, with the potential to address underlying causes of disease, reduce the severity of illness, and reduce healthcare utilization. However, current cell therapies have high upfront costs and operating expenses, requiring complex and hard-to-scale infrastructure to execute, severely limiting their accessibility and potential and costing from $30–45K USD per treatment on average. The centerpiece of regenerative therapies (including but not limited to hematopoietic, myocardial, neural, and skeletal repair therapies) is the scaffold, which acts as the growth-inducing environment for cells. However, current scaffolds such as decellularized fish skin (Kerecis, acq. US$1.3 B Jul 2023) or bovine intestines (Healthpoint, acq. US$780MM 2012) are highly complex, application-specific, and costly. There is a pressing need for novel, more cost-effective, and versatile scaffolds capable of creating more accessible and effective cell therapies.
Over US$1 MM raised in non-dilutive funding
R&D Partnerships in 7 countries
22.000 sq ft manufacturing plant commitment
2024 SXSW Pitch Finalist
2024 Hult Prize Summit Finalist
2024 Morgenthaler-Pavey Startup Competition Science Track Winner
.png)
